Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-1 in type 1 diabetes and chronic kidney disease
NL-OMON60563Phase 2Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic kidney disease (CKD) and diabetes mellitus type 1 (T1D) comparing SC0062 alone, dapagliflozin alone and dapagliflozin + SC0062 (3 arms). Primary endpoint: Change from baseline in urine albumin-creatinine ratio. Planned start Jan 2026; status: withdrawn.
02
Drugs
dapagliflozinSC0062
03
Conditions
chronic kidney disease (CKD)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON60563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60563.